Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
DLI in combination with azacitidine (75 mg/m/day for 7 days every 4 weeks) after HSCT
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Therapeutic use in overt relapse remains challenging and provides limited benefit. Prospective multicenter studies are needed to define optimal timing, dosing, and combination strategies for integrating azacitidine with DLI in this high-risk pediatric population.
[INTRODUCTION] Donor lymphocyte infusion (DLI) can enhance graft-versus-leukemia (GvL) effects following allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric acute myeloid leukemia (
- 추적기간 46.5 months
APA
Bica AM, Marcu AD, et al. (2025). Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis.. Frontiers in pharmacology, 16, 1727492. https://doi.org/10.3389/fphar.2025.1727492
MLA
Bica AM, et al.. "Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis.." Frontiers in pharmacology, vol. 16, 2025, pp. 1727492.
PMID
41585902 ↗
Abstract 한글 요약
[INTRODUCTION] Donor lymphocyte infusion (DLI) can enhance graft-versus-leukemia (GvL) effects following allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric acute myeloid leukemia (AML). However, the optimal integration of azacitidine (Aza) with DLI in children remains uncertain.
[METHODS] We retrospectively analyzed 16 pediatric AML patients (≤18 years) treated at Fundeni Clinical Institute between 2016 and 2024 who received DLI in combination with azacitidine (75 mg/m/day for 7 days every 4 weeks) after HSCT. DLI was administered prophylactically or preemptively based on mixed donor chimerism (MDC), measurable residual disease (MRD) positivity, or high-risk cytogenetics, or therapeutically for post-transplant relapse, with or without chemotherapy. Outcomes assessed included overall survival (OS), donor chimerism, relapse rate, and graft-versus-host disease (GVHD).
[RESULTS] After a median follow-up of 46.5 months, five patients received prophylactic/preemptive DLI and eleven received therapeutic DLI (seven with chemotherapy, four without). All patients in the prophylactic/preemptive group achieved full donor chimerism and MRD negativity, with an OS of 80% at 2.7 years. In the therapeutic group, median OS was 23.8 months with chemotherapy and 13.8 months without. OS differences between groups were not statistically significant (p = 0.384). Acute GVHD occurred in two patients (12.5%) in the therapeutic + chemotherapy subgroup; no chronic GVHD or non-relapse mortality was observed.
[CONCLUSION] Azacitidine combined with DLI is feasible and safe in pediatric AML after HSCT, particularly when applied prophylactically or preemptively to restore donor chimerism or eradicate MRD. Therapeutic use in overt relapse remains challenging and provides limited benefit. Prospective multicenter studies are needed to define optimal timing, dosing, and combination strategies for integrating azacitidine with DLI in this high-risk pediatric population.
[METHODS] We retrospectively analyzed 16 pediatric AML patients (≤18 years) treated at Fundeni Clinical Institute between 2016 and 2024 who received DLI in combination with azacitidine (75 mg/m/day for 7 days every 4 weeks) after HSCT. DLI was administered prophylactically or preemptively based on mixed donor chimerism (MDC), measurable residual disease (MRD) positivity, or high-risk cytogenetics, or therapeutically for post-transplant relapse, with or without chemotherapy. Outcomes assessed included overall survival (OS), donor chimerism, relapse rate, and graft-versus-host disease (GVHD).
[RESULTS] After a median follow-up of 46.5 months, five patients received prophylactic/preemptive DLI and eleven received therapeutic DLI (seven with chemotherapy, four without). All patients in the prophylactic/preemptive group achieved full donor chimerism and MRD negativity, with an OS of 80% at 2.7 years. In the therapeutic group, median OS was 23.8 months with chemotherapy and 13.8 months without. OS differences between groups were not statistically significant (p = 0.384). Acute GVHD occurred in two patients (12.5%) in the therapeutic + chemotherapy subgroup; no chronic GVHD or non-relapse mortality was observed.
[CONCLUSION] Azacitidine combined with DLI is feasible and safe in pediatric AML after HSCT, particularly when applied prophylactically or preemptively to restore donor chimerism or eradicate MRD. Therapeutic use in overt relapse remains challenging and provides limited benefit. Prospective multicenter studies are needed to define optimal timing, dosing, and combination strategies for integrating azacitidine with DLI in this high-risk pediatric population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience.
- Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
- Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States.
- Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.
- Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
- Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.